October 21, 2021 -- Johnson & Johnson and Moderna have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for booster shots of their COVID-19 vaccines.
Johnson & Johnson COVID-19 vaccine booster shots are authorized for adults ages 18 and older at least two months following primary vaccination and for eligible individuals who received a different authorized or approved COVID-19 vaccine.
The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The company has a sufficient supply to support boosting in the U.S. for all those who received primary vaccination with the Johnson & Johnson COVID-19 vaccine, the company said.
Moderna's EUA covers the use a booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for people ages 65 and older, people ages 18 to 64 who are at high risk of severe COVID-19, and people ages 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2.
Moderna's booster dose is to be administered at least six months after completion of a primary series and is also authorized for people who completed a primary vaccination with other authorized or approved COVID-19 vaccines.
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices was expected meet on October 21 to provide a potential recommendation on the rollout of COVID-19 boosters.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
